Navigation Links
Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration

PARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory News-Ipsen (Paris:IPN) announced today that the preliminary data from the ongoing phase III study for its investigational 4-month formulation of triptorelin do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients. Therefore, Ipsen has decided not to perform the second administration as planned in the protocol. No safety concerns have been observed throughout the trial. At the end of their respective monitoring period, patients will be switched to appropriate approved treatment.

The 4-month investigational product, one of Ipsen's new sustained release formulation candidates of triptorelin using one amongst several Ipsen proprietary technologies, has shown an adequate efficacy and safety profile in phase II allowing a move to phase III. Ipsen's goal remains to have a new formulation of triptorelin available when the current patents of the 3-month formulation of Decapeptyl(R) expire.

Jacques-Pierre Moreau, Executive Vice-President, Chief Scientific Officer of Ipsen said: "We are taking all appropriate actions to solve the scale-up issues seen during this phase III, which are inherent to advanced formulations based on cutting edge technologies. From the onset, the introduction of an innovative subcutaneous presentation using a new retro-injection device was well received by patients and investigators. Thus, the teams are now focusing their energy and expertise in order to resume phase III as soon as possible. Our advanced drug delivery platform has already been validated through the success of Somatuline(R) Autogel(R), and we are confident in Ipsen's ability to have a differentiated formulation of triptorelin."

About triptorelin

Triptorelin is a metabolically stabilized analogue of LHRH (Luteinizing Hormone Releasing Hormone) an hypothalamic hormone secreted in a pulsatile fashion. Upon bind
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
(Date:7/30/2014)... July 30, 2014   Medical Equipment Solutions, Corp. ... awarded a Department of Defense (US Army) contract valued ... a mobile MRI diagnostic machine and technical support staffing. ... through the Small Business Administration (SBA), Medical Equipment is ... with the latest medical diagnostic equipment. The SBA 8-A ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
(Date:7/30/2014)... 30, 2014 The Restore My Blood Sugar ... high blood sugar levels can now find an amazingly successful ... new program was created by D. Chao and Andrew Forester ... for patients when it comes to normalizing blood sugar levels. ... is a secret to the cure of diabetes that all ...
(Date:7/30/2014)... Sugar Land, TX (PRWEB) July 30, 2014 ... pharmacy recently announced their plans to move to a new ... been announced, but they will be moving soon. , MedX ... 6302 W Broadway in Pearland, TX 77581. This is the ... than their current one and will include a drive thru ...
(Date:7/30/2014)... 30, 2014 Conducting Advanced Root ... Thinking Skills and Innovative Techniques to Improve the ... and FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... #1 reason for 483 observations since 1997. , ... a successful CAPA program has never been more ...
(Date:7/30/2014)... main drug to treat malaria, is now widespread ... ( P. falciparum ) parasites that cause ... genetic mutation in the parasites. However, a six-day ... standard three-day coursehas proved highly effective in treating ... in the New England Journal of Medicine ...
(Date:7/30/2014)... 2014 (HealthDay News) -- It can happen in an instant: ... or computer monitor and gets critically injured when the furniture ... child should look around their homes and imagine what could ... it is better than it becoming a reality," Dr. Alex ... in a college news release. Between 2009 and 2011, ...
Breaking Medicine News(10 mins):Health News:Restore My Blood Sugar Review Reveals Exclusive Ways to Normalize Blood Sugar 2Health News:MedX Pharmacy Relocates to New Facility 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Tip-Over Furniture Can Kill Kids 2
... , , HARRISBURG, Pa., Aug. ... across the state on the new Integrated Care Initiative, an effort ... and Medicaid issues. , , The new health ... create a single source for consumers to work with both agencies, ...
... , MINNEAPOLIS, Aug. 4 Court ordered Class ... USA, Inc. , et al. , court File No. 27-CV-01-18042 (action filed ... in Minnesota at any time before November 30, 2004, ... A class action lawsuit involving the marketing, advertising and promotion of Marlboro ...
... , , PALO ... launch of the PEAK((R)) PlasmaBlade TnA (Tonsil and Adenoid) tissue dissection ... (FDA). This new product is indicated for cutting and coagulation of ... removal of the tonsils and adenoids. , , ...
... , ATLANTA, Aug. 4 M2SYS ... today that GHG Corporation, an innovative time tracking software provider, ... software solution. , , Bio-SnapON(TM) allows GHG ... time tracking software, known as "eTSS," to eliminate buddy punching ...
... ... introduced a new technology offering including their new Scoreboard application. The ... a glance screen showing key business indicators updated in real-time. Data ... both. The Scoreboard will be available to clients that either license ...
... NEW YORK, Aug. 4 EVO Merchant Services, a leader ... the Ernst & Young Entrepreneur Of The Year ((R)) 2009 ... LLP, the award recognizes outstanding entrepreneurs who are building and leading ... of judges, and the award was presented at a gala event ...
Cached Medicine News:Health News:Pennsylvania Department of Aging Seeks Consumer Input on New Health Care Option 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 3Health News:PEAK Surgical Introduces PEAK PlasmaBlade(TM) TnA 2Health News:PEAK Surgical Introduces PEAK PlasmaBlade(TM) TnA 3Health News:M2SYS Biometric Software Solution Selected By GHG Corporation 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 3Health News:EVO Merchant Services, CEO, Ray Sidhom Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Metro New York 2Health News:EVO Merchant Services, CEO, Ray Sidhom Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Metro New York 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: